Loading clinical trials...
Loading clinical trials...
Phase IIa Study to Evaluate the Safety and Efficacy of ABX464 Versus Placebo in Subjects With Moderate to Severe Active Ulcerative Colitis Who Have Failed or Are Intolerant to Immunomodulators, Anti-TNFα, Vedolizumab and/or Corticosteroids
Conditions
Interventions
ABX464
Placebo oral capsule
Locations
19
Austria
Univ.-Klinik für Innere Medizin I
Innsbruck, Austria
University Hospitals Leuven - campus Gasthuisberg
Leuven, Belgium
Klinické centrum ISCARE
Prague, Czechia
Orlicko-ustecka nemocnice
Ústí nad Orlicí, Czechia
CHRU de Lille
Lille, France
CHU de Nantes
Nantes, France
Start Date
November 16, 2017
Primary Completion Date
July 25, 2018
Completion Date
February 4, 2019
Last Updated
June 3, 2024
NCT07271069
NCT06975722
NCT07185009
NCT07184996
NCT07245394
NCT07089420
Lead Sponsor
Abivax S.A.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions